Coherus BioSciences Files Definitive Proxy Statement
Ticker: CHRS · Form: DEFA14A · Filed: Jan 30, 2025 · CIK: 1512762
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: CHRS
TL;DR
Coherus BioSciences (CHRS) filed its proxy statement for the annual meeting - shareholders vote soon!
AI Summary
Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on January 30, 2025, related to its annual meeting. The filing concerns the solicitation of proxies for the election of directors and other business to be conducted at the meeting. Key details regarding the company's governance and shareholder proposals are expected to be outlined within the full proxy statement.
Why It Matters
This filing is crucial for shareholders as it details the agenda for the annual meeting, including director nominations and voting matters, directly impacting corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) that provides information to shareholders and does not inherently represent a new risk to the company.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- Dennis M. Lanfear (person) — Contact Person for Business and Mail Address
- 0001104659-25-007330 (filing_id) — Accession Number for the filing
- 20250130 (date) — Filing Date
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, detailing the agenda, director nominees, and voting matters.
When was this specific DEFA14A filed by Coherus BioSciences, Inc.?
This DEFA14A filing was filed as of January 30, 2025.
Who is listed as the contact person for Coherus BioSciences, Inc. in this filing?
Dennis M. Lanfear is listed as the contact person for Coherus BioSciences, Inc. at their Redwood City, CA address.
What is the Standard Industrial Classification (SIC) code for Coherus BioSciences, Inc.?
The SIC code for Coherus BioSciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What was the former name of Coherus BioSciences, Inc.?
The former name of Coherus BioSciences, Inc. was BioGenerics, Inc., with a date of name change on February 10, 2011.
Filing Stats: 1,825 words · 7 min read · ~6 pages · Grade level 20 · Accepted 2025-01-29 20:16:07
Key Financial Figures
- $483M — ositioning for growth & value creation ~$483M Up-front UDENYCA® divestiture proc
- $250M — proceeds1 POST-CLOSE CASH PROJECTION2 ~$250M Streamlined operations 2-year cash runw
- $230M — erentiated pipeline Combinations (1+1) ~$230M Convertible notes retirement post-close
- $558.4M — to Intas Pharmaceuticals Ltd. for up to $558.4M. This transaction will strengthen Coher
- $15B — 2026 I-O Pipeline and Lifecycle Access ~$15B Market Opportunity Combinations include
Filing Documents
- tm2429853d10_defa14a.htm (DEFA14A) — 24KB
- tm2429853d10_defa14aimg001.jpg (GRAPHIC) — 381KB
- tm2429853d10_defa14aimg002.jpg (GRAPHIC) — 169KB
- tm2429853d10_defa14aimg003.jpg (GRAPHIC) — 310KB
- 0001104659-25-007330.txt ( ) — 1209KB
forward-looking statements, although not all forward-looking statements contain
forward-looking statements, although not all forward-looking statements contain these identifying words. You can also identify forward-looking statements by discussions of strategy, plans or intentions. Examples of such forward-looking regarding: the proposed transaction and related matters, including, but not limited to, the ability to satisfy the closing conditions to consummate the proposed transaction at all or in the estimated time; prospective performance and opportunities with respect to the Company or its business following the closing of the proposed transaction; post-closing operations and the outlook for the Company, including with respect to growth and value creation; the Company’s targets, plans, objectives or goals for future operations, including for LOQTORZI, the Company’s product candidates, research and development, and product candidate approvals; the Company’s projection for post-close cash, including the components of that projection; projections of UDENYCA divestiture proceeds and the Company’s planned uses for those proceeds; projections of time for a cash runway and statements regarding the Company’s ability to reduce expenses it uses in its operations in the future; projections of market opportunity; and These forward-looking statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, assumptions and changes in circumstances, many of which are beyond the control of the Company. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may